Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status.

Penn, Courtney A; Carballo, Erica V; Walsh, Christine S; Zivanovic, Oliver; Kim, Kenneth H

Penn, Courtney A; Carballo, Erica V; Walsh, Christine S; Zivanovic, Oliver; Kim, Kenneth H.

Afiliação

Penn CA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA.
Carballo EV; Department of Obstetrics and Gynecology, Emory University School of Medicine, Atlanta, GA, USA.
Walsh CS; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Denver, CO, USA.
Zivanovic O; Division of Gynecologic Oncology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kim KH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Gynecol Oncol Rep ; 41: 101009, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35652061

Palavras-chave

CEA, Cost-Effectiveness Analysis; HIPEC, Hyperthermic Intraperitoneal Chemotherapy; PCS, Primary Cytoreductive Surgery

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google